Apolipoprotein B (Apo B) is becoming an essential marker for evaluating and managing complex lipid disorders. Its importance continues to grow. Clinicians increasingly recognize Apo B’s ability to provide clearer insights into atherosclerosis risk compared to traditional lipid panels.
The recommendations for using Apo B in dyslipidemia management reflect advances in lipidology. These updates, originally published by the National Lipid Association in April 2015 (Part 1), remain highly relevant today. Apo B quantifies the number of atherogenic lipoprotein particles, offering critical insights that LDL cholesterol (LDL-C) alone cannot.
Unlike LDL-C, which measures the cholesterol within lipoproteins, Apo B directly counts atherogenic particles. Each LDL, VLDL, and IDL particle contains exactly one Apo B molecule. This makes Apo B a reliable marker for the particles driving atherosclerosis. Elevated Apo B levels indicate higher cardiovascular risk, even when LDL-C appears normal.
Standard lipid panels often fail to capture this risk. For example, patients with high triglycerides or small, dense LDL particles can have normal LDL-C levels but elevated Apo B. This discordance leaves residual cardiovascular risk undetected. Apo B addresses these limitations by measuring the actual particle count, giving a more accurate risk assessment.
Apo B also guides treatment more effectively than traditional markers. Studies show that reducing Apo B correlates more strongly with cardiovascular risk reduction than lowering LDL-C alone. Clinicians can use Apo B to personalize therapies, including statins and newer treatments targeting lipoprotein particles.
Patients with metabolic syndrome, diabetes, or mixed dyslipidemia particularly benefit from Apo B testing. These groups often show discordant LDL-C and non-HDL-C levels, making Apo B a critical tool. Tracking Apo B levels helps refine treatment plans and monitor progress with precision.
I expect Apo B to become a standard part of dyslipidemia management in the near future. Its particle-based approach addresses gaps in traditional lipid testing, especially for high-risk patients. Apo B complements LDL-C and non-HDL-C, often providing superior insight into atherogenic burden.
The National Lipid Association’s 2015 guidelines marked a turning point for Apo B recognition. Ongoing research continues to highlight its value in cardiovascular risk assessment. As clinical adoption grows, Apo B will empower more effective, personalized care for patients with complex lipid disorders.
Excerpts from 2015 NLA Guidelines, Part 1
Apo B is considered an optional, secondary target for treatment. Epidemiologic studies have generally shown that both apo B and non–HDL are better predictors of ASCVD risk than LDL-C. Because each potentially atherogenic lipoprotein particle contains a single molecule of apo B, the apo B concentration is a direct indicator of the number of circulating particles with atherogenic potential. Apo B and non–HDL share the advantage that neither requires fasting for accurate assessment. Non–HDL is favored over apo B by the NLA Expert Panel because it is universally available, requiring no additional expense compared with the standard lipid profile, and because apo B has not been consistently superior to non–HDL in predicting ASCVD event risk.
Cholesterol-lowering drug therapies, especially statins, alter the relationship between atherogenic cholesterol and apo B, often lowering the cholesterol concentration more than the apo B level. Apo B is a potential contributor to residual ASCVD risk because it may remain elevated in some individuals who have attained their treatment goals for non–HDL and LDL-C, particularly in patients with high triglycerides and low HDL levels. A clinical trial assessing the ability of more aggressive lipid management to lower residual risk in patients on statin therapy, but with residual elevation in apo B (and/or LDL particle concentration), is needed.
An examination of LDL-C, non–HDL-C, apo B, and LDL-particle concentrations among 27,533 apparently healthy women in the Women’s Health Study demonstrated reasonably high correlations between LDL-C and each of the alternate measures (non–HDL-C, apo B, and LDL particle concentration), but substantial discordance between measurements in some individuals. For those with concordant levels of LDL-C and non–HDL-C, apo B, or LDL particle concentration, the clinical utility of these measures for estimating coronary risk was similar. However, among the subgroups of subjects with discordance of LDL-C with another atherogenic lipoprotein-related measure such as non–HDL-C, apo B, or LDL particle concentration (11%-24% depending on the measure used), ASCVD risk was either over- or under-estimated by 20-50% compared with LDL-C alone. Discordance has been defined variably in research conducted to date (eg, median cut points or guideline cut points). Additional research will be needed to further elucidate the clinical importance of discordance between measures of atherogenic lipoprotein burden.
If apo B is used as an optional target for treatment, goals are <90 mg/dL for primary prevention and <80 mg/dL for those with very high risk, although measurement of apo B is generally not necessary until the patient has been treated to his or her goal levels for atherogenic cholesterol. The thresholds for these cut points represent the panel’s consensus based on an evaluation of the available evidence and are consistent with those recommended previously by the American Diabetes Association/ ACC Foundation. Treatment with statins and other cholesterol-lowering drug therapies appears to alter the relationship between atherogenic cholesterol and apo B concentrations.
In an analysis of data from the Limiting Undertreatment of Lipids in ACS with Rosuvastatin (LUNAR) trial, authors reported that during statin therapy, an apo B concentration of 90 mg/dL was associated with mean LDL-C and non–HDL concentrations of 85 and 105 mg/dL, respectively. The corresponding mean values associated with an apo B concentration of 80 mg/dL were 74 mg/dL for LDL-C and 92 mg/dL for non–HDL-C. As discussed previously, patients who remain above the apo B goals, despite having reached their atherogenic cholesterol goals, are discordant and may therefore have residual risk related to an elevated concentration of circulating particles with atherogenic potential.
Clinicians may consider measuring LDL-particle concentration as an alternative to apo B. Apo B and LDL-particle concentration have been reported to perform similarly with regard to the prediction of increased ASCVD risk. The NLA Expert Panel acknowledges that measurement of LDL particle concentration can be useful clinically, particularly once non–HDL and LDL-C goals have been attained, as another potential indicator of residual risk for ASCVD. The Centers for Disease Control–National Heart, Lung, and Blood Institute has standardization programs for LDL-C, non–HDL-C, and apo B measurements. A similar standardization program for LDL particle concentration has not yet been established. Most studies of LDL particle concentration published to date have used a proprietary nuclear magnetic resonance method, but other proprietary methodologies for LDL particle concentration quantification are also available. These various methods appear to have variable agreement in terms of LDL particle size, and their performance for predicting ASCVD risk has not been directly compared.
Accordingly, the NLA Expert Panel did not recommend treatment goals for LDL particle concentration. Additional information about the clinical use of LDL particle concentration may be found in a report issued by another panel of NLA experts: Clinical Utility of Inflammatory Markers and Advanced Lipoprotein Testing: Advice from an Expert Panel of Lipid Specialists.